Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 3/20 | 0.38 |
| ▸ | MDM4 | O15151 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30686160 | 1.00 | FABP5 (0.38) | FABP5FABP7CASP3MDM4TP53 | |
| SCHEMBL30744237 | 1.00 | FABP5 (0.38) | FABP5FABP7CASP3MDM4TP53 | |
| SCHEMBL20604252 | 1.00 | FABP5 (0.38) | FABP5FABP7CASP3MDM4TP53 | |
| SCHEMBL16288775 | 1.00 | FABP5 (0.38) | FABP5FABP7CASP3MDM4TP53 | |
| SCHEMBL25179599 | 0.91 | CASP3 (0.38) | FABP5FABP7CASP3MDM4TP53 | |
| SCHEMBL25179598 | 0.91 | CASP3 (0.38) | FABP5FABP7CASP3MDM4TP53 | |
| SCHEMBL30802516 | 0.91 | CASP3 (0.38) | FABP5FABP7CASP3MDM4TP53 | |
| SCHEMBL16310687 | 0.88 | FABP5 (0.40) | FABP5FABP7CASP3MDM4TP53 | |
| SCHEMBL24633869 | 0.87 | FABP5 (0.43) | FABP5FABP7CASP3MDM4TP53 | |
| SCHEMBL30792912 | 0.87 | FABP5 (0.43) | FABP5FABP7CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-117279933-A | Cyclic compounds having selective KRAS inhibition relative to HRAS and NRAS | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-3424941-A1 | PRODUCTION METHOD FOR NONCYCLIC PEPTIDE-NUCLEIC ACID COMPLEX HAVING, AT N-TERMINAL, AMINO ACID WITH THIOL GROUP NEAR AMINO GROUP, LIBRARY THEREOF, AND CYCLIC PEPTIDE-NUCLEIC ACID COMPLEX LIBRARY DERIVED FROM SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2019-01-09 | — | — | EP | disclosed |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | FABP5 2565/4885FABP7 3166/4885CASP3 343/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | FABP5 4094/4885FABP7 4602/4885CASP3 3906/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | FABP5 4094/4885FABP7 4602/4885CASP3 3906/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | FABP5 2565/4885FABP7 3166/4885CASP3 343/4885 |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | FABP5 2565/4885FABP7 3166/4885CASP3 343/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | FABP5 4026/4885FABP7 4376/4885CASP3 3268/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | FABP5 2565/4885FABP7 3166/4885CASP3 343/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | FABP5 4094/4885FABP7 4602/4885CASP3 3906/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | FABP5 2565/4885FABP7 3166/4885CASP3 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.